NASH Drugs Market

NASH Drugs Market, 2015 - 2025

  • Lowest Price Guaranteed From USD 2,199

  • Companies Covered
    77

  • Pages
    188

  • View Count
    9013

NASH Drugs Market Overview

The global NASH drugs market  or non-alcoholic steatohepatitis treatment market is likely to be worth $20 - $30 billion by 2025. NASH or non alcoholic steatohepatitis treatment refers to a chronic liver disorder characterized by accretion of fat (lipid droplets), along with inflammation and degeneration of hepatocytes. In other words, it can be defined as significant steatohepatitis not caused due to alcohol, drugs, toxins, infectious agents or other identifiable exogenous causes. NASH is often accompanied with a high possibility of cirrhosis, a condition in which the liver functions are changed, leading to liver insufficiency. Although NASH has become quite common, there is still no clarity about the underlying cause of the disease. It is currently the third most common factor leading to liver transplants in the US. Estimated to affect around 2-5% of Americans, NASH has been cited as the next hepatitis C.

Given the rising prevalence of NASH, it has become all the more crucial to understand the pathophysiology of NASH in order to develop therapeutic interventions. Several options are being investigated to identify an efficient treatment regimen for NASH; these include lifestyle modifications, off-label therapies, natural products and combinations of these approaches. However, the diagnostic landscape for NASH is quite challenging; majority of the patients are asymptomatic and can only be detected by routine blood tests showing elevations in liver enzymes. At present, liver biopsy is being used as the only reliable way to diagnose NASH and detect the presence of fibrosis; however, very few patients choose to undergo liver biopsy because of its invasive nature.

Recognizing the huge unmet medical need, several companies are striving to establish an early foothold in the area. Investigators are also looking forward to exploiting the approach of personalized medicine in order to identify diagnostic biomarkers, prognostic biomarkers and therapeutic targets for the treatment of NASH on the basis of their pathogenic and clinical traits. Owing to the above-mentioned reasons, NASH drugs market  / non-alcoholic steatohepatitis treatment market likely to witness substantial market growth during the forecast period.

Recent Developments in NASH Drugs Market:

Several recent developments have taken place in the field of NASH drugs market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In June 2023, Madrigal Pharmaceuticals submitted new drug application to FDA seeking accelerated approval of Resmetirom for the treatment of NASH with liver fibrosis. 
  • In May 2023, Boston Pharmaceuticals announced acceptance of late-breaking abstract highlighting new phase 2 clinical data from BOS-580 NASH Program at EASL 2023. 
  • In April 2023, FDA granted Madrigal Pharmaceuticals’ Resmetirom a breakthrough therapy designation for non alcoholic steatohepatitis treatment (NASH) with liver fibrosis.

Scope of the Report

The ‘NASH Drugs Market, 2015-2025’ market report provides a comprehensive study on the current market landscape, NASH market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the NASH drugs market. With an expanding NAFLD and NASH population worldwide, there is a growing need for development of therapeutics in this disease area. NASH is gradually emerging as the leading cause of liver transplants. While the field has garnered interest of several companies, there are no approved therapies till date. It is important to stress that the development pipeline of NASH has several promising candidates that are likely to result in many commercial success stories in the foreseen future.

Amongst other elements, the market research report elaborates on the new diagnostic solutions being developed and the upcoming opportunities for different stakeholders. As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this market report is to understand the future potential of the non-alcoholic steatohepatitis treatment market. This is done by analyzing:

  • The epidemiology, patient population and staging of NASH in different geographies.
  • The NASH pipeline in terms of phase of development, type of molecule, route of administration and mechanism of action.
  • The likely evolution in the rate of diagnosis, drug treated patient population and the likely price of the drugs.
  • The associated constraints, in terms of undefined pathogenesis and the unavailability of non-invasive diagnostic tests, and the initiatives being carried out by the companies to overcome these.

The key objective of NASH drugs market report is to provide a detailed market analysis in order to estimate the existing NASH market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for non-alcoholic steatohepatitis treatment market during the forecast period. The research, analysis and insights presented in this market research report include potential sales of the drugs in late stages of development and expected to launch by 2025. Our opinions and insights, presented in this study, were influenced by the discussions that we conducted with experts in this area. These included senior representatives at BiOrion Technologies, Phenex Pharmaceuticals, Tobira Therapeutics, Verlyx Pharmaceuticals and Connexios.

All actual figures have been sourced and analyzed from publicly available information and discussions with industry experts. The figures mentioned in this report are in USD, unless otherwise specified.

PRICING DETAILS

USD 2,199

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
click for sending an email to Roots Analysis team sales@rootsanalysis.com